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Allogeneic hematopoietic stem cell
transplantation
A B S T R A C T
A 17-year-old male received allogeneic transplantation for acute lymphoblastic leukemia, and presented with
generalized seizures due to a solitary brain lesion with massive necrosis on day +621. Epstein–Barr virus (EBV)
DNA copies were below the cut-off value in plasma. Stereotactic biopsy of the cerebral lesion confirmed the
diagnosis of post-transplant lymphoproliferative disorder (PTLD) with large atypical cells positive for CD20 and
EBER. In order to diagnose primary central nervous system PTLD, the biopsy should be applied as early as
possible when brain lesion with necrosis develops in post-transplant patients regardless of EBV-DNA in plasma.
1. Introduction
Post-transplant lymphoproliferative disorder (PTLD) is character-
ized by lymphoid or plasmacytic proliferation in a recipient after allo-
geneic hematopoietic stem cell transplantation (allo-HSCT) or solid
organ transplantation. PTLD is regarded as one of the most serious post-
transplant complications due to its high mortality [1]; therefore, an
early diagnosis is important for the initiation of optimal interventions.
In most cases, the outgrowth of donor-derived Epstein–Barr virus
(EBV)-infected B cells results in the development of PTLD. EBV DNA
monitoring using the quantitative polymerase chain reaction (qPCR)
method was previously reported to be a sensitive modality for the early
diagnosis of EBV-positive PTLD [1,2] because patients at an increased
risk of overt PTLD development presented with EBV reactivation.
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Although different assays using whole blood, plasma, and peripheral
blood mononuclear cells (PBMC) have been used to monitor EBV-po-
sitive PTLD, the qPCR method for EBV DNA in plasma is regarded as a
more reliable assay than that in PBMC [3].
PTLD is a rare complication with an incidence of 1–3% among re-
cipients after allo-HSCT [2,4] and represents a clinical heterogeneous
manifestation. Due to the limited amount of information on primary
central nervous system PTLD (CNS-PTLD) after allo-HSCT, the diag-
nostic value of EBV DNA copies in post-transplant patients with CNS-
PTLD remains poorly understood.
We herein report a case of CNS-PTLD after allo-HSCT for which the
qPCR method in PBMC, plasma, and cerebrospinal fluid (CSF) showed
less evidence of EBV reactivation.
2. Case report
A 17-year-old male was diagnosed with acute T cell lymphoblastic
leukemia (ALL) with the normal karyotype and SIL-TAL1 chimeric
transcription. A CSF examination showed no evidence of CNS involve-
ment. The patient achieved complete remission after induction therapy;
however, due to allergies to methotrexate and L-asparaginase, he was
unable to receive the standard consolidation program. Human leuko-
cyte antigen 7/8 allele-matched (Cw-mismatched) unrelated bone
marrow transplantation from a female donor without any T-cell de-
pletion was performed using a myeloablative conditioning regimen
(cyclophosphamide 120mg/kg and total body irradiation 12 Gy/6 fr.).
Tacrolimus and mycophenolate mofetil (MMF) were used as graft-
versus-host disease (GVHD) prophylaxis. Neutrophil engraftment was
achieved on day +12 and an XY-fluorescence in situ hybridization
analysis revealed complete donor chimerism. He developed acute
GVHD grade II on day +32, and the administration of prednisolone at
1.0 mg/kg was initiated.
The patient presented with the disturbance of consciousness due to
generalized seizures during the GVHD treatment with tacrolimus
1.5 mg, prednisolone 7.5mg, and MMF 2000mg daily on day +621
after allo-HSCT. A peripheral blood count yielded a leukocyte count of
3.7× 109/L, consisting of 26% neutrophils, 49% lymphocytes, and
25% monocytes; hemoglobin level, 13.6 g/dL; platelet count,
181 × 109/L. A lymphocyte subset analysis by flow cytometry showed
that the percentages of CD22-positive cells, CD3-positive cells, and
CD56-positive cells were 9.1, 81.3, and 12.1%, respectively. Magnetic
resonance imaging (MRI) of the brain revealed a space-occupying lesion
with ring enhancement and perifocal edema in the left front-parietal
lobe (Fig. 1A, B), indicating several differential diagnoses, including
opportunistic infections, PTLD, and the extramedullary relapse of ALL.
Routine microbiological tests to detect bacteria, fungi, toxoplasma IgG,
and interferon-gamma in blood samples were negative. The cell count
in CSF was 4/mm3 with small mononuclear cells. The EBV serostatus
was as follows: anti-EA-DR IgG < × 10; anti-VCA IgM < × 10, anti-
VCA IgG × 20, and anti-EBNA-IgG < × 10.
PBMC were separated after a Ficoll-Hypaque density gradient; and
CD19-, CD3-, and CD56-positive cells were selected using im-
munomagnetic beads (Dynabeads M-450, Veritas, Tokyo, Japan.). DNA
was extracted from PBMC, selected cells, whole blood, the plasma
fraction, and CSF. A PCR assay was performed using the Taq-Man PCR
kit (PE Applied Biosystems, Foster City, Calif.), as previously described
[5]. EBV DNA copy numbers in plasma and CSF were below the cut-off
value (1.0× 102 copies/ml) (Table 1). The EBV DNA copy number was
1.1×102 copies/105 PBMC. The qPCR assay revealed that the EBV
DNA copy number in the CD19-positive cell fraction was elevated
(2.8×103 copies/105 cells), whereas those in the CD3- and CD56-po-
sitive cell fractions were not. A bone marrow examination showed
complete donor chimerism and no evidence of ALL relapse due to the
absence of SIL-TAL1 chimeric transcription. Stereotactic biopsy of the
cerebral lesion confirmed the diagnosis of monomorphic PTLD with
massive necrosis and large atypical cell proliferation.
Immunohistochemical staining showed that large atypical cells were
positive for CD20 and negative for CD3. A small number of EBV-en-
coded small RNA (EBER)-positive cells were detected (Fig. 1C–F). The
biopsy sample was too small to evaluate the origin of PTLD cells by XY-
fluorescence in situ hybridization.
To treat CNS-PTLD, tacrolimus was reduced, whereas difficulties
were associated with the cessation of immune suppressants because of
the progression of chronic GVHD. MRI of the brain showed an enlarged
tumor on day +840, which indicated the progression of CNS-PTLD. He
did not respond to three courses of the weekly administration of ri-
tuximab (375mg/m2). Local irradiation therapy (20 Gy/10 fr.) for CNS-
PTLD was subsequently initiated on day +931, but was stopped after 5
fractions because of sepsis and progressive GVHD, and the patient died
of multiorgan dysfunction on day +1018.
3. Discussion
The present case developed CNS-PTLD from day 620 after allo-
HSCT, with the use of an unrelated bone marrow graft and the pro-
longed administration of immunosuppressive agents being risk factors
for PTLD [1]. Among 580 patients who underwent their first allo-HSCT
at the Nagasaki Transplant Group between January 1, 1990 and April
31, 2018, we encountered the first case of CNS-PTLD (0.17%), which
was in line with its rarity after allo-HSCT, as previously reported [6]. In
terms of a detailed analysis to detect EBV DNA and MRI findings, our
results provided important insights into diagnostic modalities for CNS-
PTLD.
The most interesting result of this case was that EBV DNA copy
numbers in plasma and CSF remained below the cut-off value. This
result was not consistent with the findings of a previous study on a large
cohort showing that the EBV DNA copy number in plasma was a more
sensitive marker to diagnose EBV-related diseases, including PTLD
[1,3]. One possible reason for the present results was that EBV DNA in
plasma was insufficient to reflect virus shedding from the CNS lesion.
This has also been reported in cases of CNS-PTLD after solid organ
transplantation [7]. Therefore, our results suggest that the careful in-
terpretation of EBV DNA in plasma is needed when attempting to di-
agnose CNS-PTLD among post-transplant patients.
EBV DNA copy numbers in PBMC in the present case were lower
than those in cases of EBV-positive PTLD without CNS lesions, although
the early symptom of EBV-positive PTLD is frequently increasing levels
of EBV DNA copies in PBMC [3]. This result of the present case was, at
least in part, due to the lower percentage of the B-cell fraction in the
lymphocyte subset during intensive immunosuppressive treatment for
active GVHD. Based on these results in the present case, the monitoring
assays for EBV DNA in plasma and PBMC using qPCR may be in-
sufficient to establish a probable diagnosis of CNS-PTLD after allo-
HSCT.
Ring enhancement on MRI was observed in between 4 and 11% of
patients with primary CNS lymphoma, and in approximately 75% of
PCNSL in immunocompromised patients, such as post-transplant and
human immunodeficiency virus (HIV)-infected patients [8]. These MRI
findings reflect pathological findings that CNS-PTLD may have necrotic
lesions [9]. We also considered differential diagnoses, such as tox-
oplasmosis, abscess, tuberculosis, relapsed ALL, and PTLD. Based on the
diagnostic value of EBV DNA in plasma and PBMC, it is important to
note that early biopsy of brain lesions needs to be considered for post-
transplant patients who developed brain mass lesions with ring en-
hancement in order to accurately diagnose CNS-PTLD. Since recent
studies reported that the intrathecal administration of rituximab was
effective for CNS-PTLD [10], early biopsy after MRI may be a promising
diagnostic modality for the provision of specific therapy.
In conclusion, CNS-PTLD needs to be considered in post-transplant
patients who present with brain mass lesions with ring enhancement as
well as the early biopsy of cerebral lesions regardless of the EBV DNA
copy number. Further clinical and experimental investigations are
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required to develop optimal monitoring methods and diagnostic mod-
alities for CNS-PTLD.
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